Triple Therapy for Type 2 Approved


By: Daniel Trecroci

The U.S. Food and Drug Administration has approved a new indication for Glucovance (glyburide and metformin tablets), allowing the type 2 diabetes medication to be taken in combination with thiazolidinediones (TZDs) when adequate control is not achieved with diet and exercise.

According to an October 11, 2002, news release from Bristol-Myers Squibb (BMS), the drug’s manufacturer, clinical studies report that 42 percent of people with type 2 diabetes taking Glucovance with Avandia (rosiglitazone) achieved an A1C level of 7% or less.

BMS cautions that, in rare cases, Glucovance can cause lactic acidosis (a buildup of lactic acid in the blood), which can be fatal. People should not take Glucovance if they have kidney problems; if they are over 80 years of age (unless their kidneys have been tested); if they are taking medication for heart failure; or if they are seriously dehydrated, have a serious infection or have had liver disease. The most common side effect is diarrhea. People should not take Avandia or other TZDs unless laboratory tests show normal liver function.



Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.